



Item 1 – Cover Page

ADV Part 2A and B: FIRM BROCHURE

Linden Manager LLC

111 S. Wacker Dr.

Suite 3350

Chicago IL 60606

(312) 506-5600 (phone)

(312) 506-5601 (facsimile)

www.lindenllc.com

March 30, 2012

This Brochure provides information about the qualifications and business practices of Linden Manager LLC (referred to herein as “Adviser” or “Linden” d/b/a “Linden Capital Partners” and “Linden LLC”). If you have any questions about the contents of this Brochure, please contact us at (312) 506-5600. The information in this Brochure has not been approved or verified by the United States Securities and Exchange Commission or by any state securities authority.

Linden is a registered investment adviser. Registration of an investment adviser with the SEC does not imply any level of skill or training. The oral and written communications of an adviser provide you with information about which you determine to hire or retain an adviser.

Additional information about Linden also is available on the SEC’s website at www.adviserinfo.sec.gov.

Item 2 – Material Changes

The Securities and Exchange Commission requires registered investment advisers to provide clients with Form ADV Part 2, which contains a clearly written and meaningful disclosure, in plain English, about the adviser's business practices, conflicts of interest and advisory personnel. The Form ADV 2 is divided into two parts, Part 2A and Part 2B. Part 2A of the Form (the "Firm Brochure") provides information about a variety of topics relating to an adviser's business practices and conflicts of interest. Part 2B of the Form (the "Brochure Supplement") requires an adviser to provide information about certain advisory personnel.

Linden believes that communication and transparency are of the utmost importance and continually strives to provide limited partners with complete and accurate information at all times. Linden encourages all current and prospective limited partners to read this Firm Brochure and to discuss any questions that may arise.

This is Linden's initial filing of the Firm Brochure. In the future, this item will discuss only specific material changes that are made to the Brochure and provide clients with a summary of such changes. Linden will also reference the date of its last annual update of its Brochure. Linden will ensure that clients receive an annual updated Brochure or a summary of any material changes to this and subsequent Brochures within 120 days of the close of Linden's fiscal year. Linden may further provide other ongoing disclosure information about material changes as necessary and without charge.

Currently, Linden's Brochure may be requested by contacting Linden's Chief Compliance Officer, Doug VanDegrift at (312) 506-5600. The Brochure is also available, free of charge, from the SEC's Investment Adviser's Public Disclosure Website (www.adviserinfo.sec.gov). The SEC's website also provides information about any persons affiliated with Linden who are registered as investment adviser representatives of Linden.

Item 3 -Table of Contents

	<u>Page</u>
Item 1 – Cover Page	i
Item 2 – Material Changes.....	ii
Item 3 – Table of Contents	iii
Item 4 – Advisery Business	1
Item 5 – Fees and Compensation.....	1
Item 6 – Performance-Based Fees and Side-By-Side Management	2
Item 7 – Types of Clients	2
Item 8 – Methods of Analysis, Investment Strategies and Risk of Loss	3
Item 9 – Disciplinary Information	6
Item 10 – Other Financial Industry Activities and Affiliations	6
Item 11 – Code of Ethics	7
Item 12 – Brokerage Practices	9
Item 13 – Review of Accounts	9
Item 14 – Client Referrals and Other Compensation	10
Item 15 – Custody.....	10
Item 16 – Investment Discretion	11
Item 17 – Voting Client Securities	11
Item 18 – Financial Information	11
Brochure Supplement(s)	

Item 4 – Advisory Business

Firm Description

Founded in 2004, Linden Capital Partners and its related entities are a Chicago-based middle market private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden Manager LLC's predecessor entity, Linden Life Science LLC, was founded in 2002. Linden Manager LLC (referred to herein as "Adviser" or "Linden") currently manages four limited partnerships (collectively referred to herein as the "Funds"): Linden Capital Partners LP ("Linden I"), Linden Capital Partners - A LP ("Linden I-A," and together with Linden I, "Fund I"), Linden Capital Partners II LP ("Linden II") and Linden Capital Partners II-A LP ("Linden II-A," and together with Linden II, "Fund II") with combined commitments of \$575 million. Linden's strategy is based upon three elements: (i) healthcare and life science industry specialization, (ii) integrated private equity and operating expertise, and (iii) strategic relationships with large corporations. Linden, through its Funds, invests in healthcare companies that can benefit from strategic redirection, capital investment, operational improvements, acquisitions and additions to the management team. Utilizing this strategy, Linden, in partnership with experienced industry executives, seeks to make initial platform investments at attractive valuations and to substantially improve company profitability through increased revenues and improved margins. Linden also seeks to make add-on acquisitions after validating the initial platform investment, the management team and the successful transition to private equity ownership.

As of December 31, 2011, Linden had assets under management of \$575 million¹ all of which are managed in Linden's sole discretion.

Principal Owners/Ownership Structure

Linden Manager LLC is founded and owned by Anthony Davis, Eric Larson and Brian Miller.

Item 5 – Fees and Compensation

The specific manner in which Linden or its related entities charges fees is established in a limited partner's written agreement with the Firm.

Generally, on a semi-annual basis, Linden or its related entities will charge each client a fee for managing the portfolio ("Management Fee"). This fee is billed partially in advance semi-annually on January 5th and July 5th of each calendar year and partially in arrears. While each Fund is in its investment period (a length six years after Management Fees are initially charged), the Management Fee is equal to 2% of investor commitments. After the investment period has expired, the Management Fee is equal to 2% of invested capital. In the case where an investment has been completely written off or is no longer in the portfolio, it is not included in the invested capital fee

¹ AUM calculations may differ from those used in other regulatory filings by Linden in accordance with applicable requirements and guidelines.

base. The Management Fee is paid out of current income, as well as from the disposition proceeds of each respective Fund and from drawdowns that reduce each limited partner's capital contribution. At its discretion, Linden may waive all or a portion of its management fee.

In addition, limited partners in Funds I and II are responsible for organizational and startup expenses, up to a maximum of \$750,000 for Fund I and \$1 million for Fund II. Any expenses in excess of those limits, dollar for dollar, reduce the Management Fee. Limited partners in Funds I and II are also responsible for all costs, expenses, liabilities and obligations relating to their activities, investments and business, including (i) all costs expenses, liabilities and obligations attributable to acquiring, holding and disposing of investments (including interest on money borrowed, registration expenses and brokerage, finders', custodial and other fees) (ii) legal, auditing, consulting, insurance, travel, litigation and indemnification costs and expenses, financing, appraisal, filing, accounting and custodian fees and expenses; expenses associated with the respective Funds' financial statements, tax returns and Schedule K-1s; (iii) out-of-pocket expenses incurred in connection with transactions not consummated; (iv) expenses of the advisory board and meeting of the limited partners; (v) any taxes, fees or other governmental charges levied upon such Fund.

Item 6 – Performance-Based Fees and Side-By-Side Management

Linden's related entities have entered into performance fee arrangements with each Fund's limited partners. Such fees are based on the terms in each investor's written agreement with these related entities, as well as each Fund's private placement memorandum. These performance or incentive fee arrangements have been structured subject to Section 205(a)(1) of the Investment Advisers Act of 1940 ("The Advisers Act") in accordance with the available exemptions thereunder, including the exemption set forth in Rule 205-3.

If total proceeds from the sale of Fund investments exceed the sum of cash contributions made by such Fund's investors plus a preferred return on those cash contributions, the Firm, or its related entities, is allocated 20% of that excess profit, known as carried interest. Carried interest is subject to claw-backs to the extent Linden or its related entities are paid in excess of their entitled distribution.

Linden's management fees, carried interest allocations, performances fees and other compensation payable to Linden and its related entities are established by Linden at the time of the establishment of the relevant vehicle and are negotiated with participating investors prior to making their investment. Once the relevant Fund has been established and commenced operations, such compensation and expenses are generally not negotiable.

Because limited partners are only charged a management fee and performance-based fee, and not another type of fee such as an hourly or flat fee or asset-based fee, Linden faces no conflict of interest in favoring performance-based fee accounts over other types of accounts.

Item 7 – Types of Clients

Linden provides portfolio management services to its private fund clients, the Linden Funds. Linden Manager LLC provides portfolio management services and Linden Manager LP and Linden

Manager II LP act as the general partner to the Fund I and Fund II, respectively. The Funds limit their respective investors to persons who are both “accredited investors” as defined in the Securities Act of 1933 and “qualified purchasers” as defined in the Advisers Act. Minimum commitments for a limited partner to Fund I and Fund II were \$1 million and \$5 million, respectively, which may have been reduced at Linden’s discretion. The Funds are no longer accepting new commitments from investors.

Investors in Linden Funds include a broad range of U.S. and non-U.S. investors, including, among others, fund of funds, high net worth individuals, corporate pension and profit-sharing plans, charitable institutions, foundations, endowments, municipalities, trust programs, foreign funds and other U.S. and international institutions. In addition, employees and other persons associated with Linden and/or its affiliates may make capital contributions to the Funds.

Item 8 – Methods of Analysis, Investment Strategies and Risk of Loss

Strategy

Linden’s strategy is based upon three elements: (i) healthcare and life science industry specialization, (ii) integrated private equity and operating expertise, and (iii) strategic relationships with large corporations. Linden, through its Funds, invests in healthcare companies that can benefit from strategic redirection, capital investment, operational improvements, acquisitions and additions to the management team. Utilizing this strategy, Linden, in partnership with experienced industry executives, seeks to make initial platform investments at attractive valuations and to substantially improve company profitability through increased revenues and improved margins. Linden also seeks to make add-on acquisitions after validating the initial platform investment, the management team and the successful transition to private equity ownership. Investments in these types of business are made with a long-term view and an anticipated holding period of greater than two years.

Linden focuses on forming long-term relationships with CEOs, CFOs, board members and key business unit managers of healthcare and life science companies, which are often sellers, future buyers, suppliers or customers of our current and future portfolio. The team has built a competitive advantage in its ability to source transactions through its corporate relationship program, high certainty-of-close track record, and its ability to execute complex carve-out transactions. Corporate divestitures often require greater management attention post-acquisition than do other private equity investments, and the team has built an expertise in sourcing and managing this type of investment.

Linden adheres to a rigorous, disciplined and analytical process to qualify and evaluate investments. Every investment opportunity presented in Linden’s weekly meeting is scored on four primary dimensions: (i) the overall attractiveness of the business, including an assessment of the industry and management team; (ii) the competitiveness of the transaction process; (iii) Linden’s competitive advantage and strategic angle, and (iv) the anticipated valuation.

Risk Factors

No investment is free of risk. Current and prospective Linden limited partners are cautioned that investments in securities involve risk of loss, including the possibility of a complete loss of the amount invested, and that they should be prepared to bear these risks. All investors should be aware of certain risk factors, which include, but are not limited to:

- Business Risks: The Funds' investment portfolio will consist primarily of securities issued by privately held companies, and operating results in a specified period will be difficult to predict. Such investments involve a high degree of business and financial risk, which can result in substantial loss.
- Future and Past Performance: The performance of the members of the Linden team's prior investments is not necessarily indicative of any Fund's future results. While Linden intends for its Funds to make investments that have estimated returns commensurate with the risks undertaken, there can be no assurances that the targeted internal rate of return will be achieved. There can be no assurance that any limited partner will receive any distribution from any Fund. On any given investment, loss of principal is possible.
- Concentration of Investments: The Funds are invested in a limited number of investments and intends for all investments to be made in healthcare, life science and other science-based businesses. As a consequence, the Partnership will be less diversified for industry risk than other, more broadly focused funds. The Fund's healthcare and life science investments may be exposed to risk from changes in government regulations and reimbursement policies. Each Fund's investment portfolio could become highly concentrated, and the performance of a few holdings may substantially affect its aggregate return.
- Investment in Junior Securities: The securities in which the Funds will invest may be among the most junior in a portfolio company's capital structure and, thus, subject to the greatest risk of loss. Generally, there will be no collateral to protect an investment once made.
- Lack of Sufficient Investment Opportunities: It is possible that a Fund may never be fully invested if enough sufficiently attractive investments are not identified. The business of identifying and structuring private equity transactions is highly competitive and involves a high degree of uncertainty. Limited partners, however, are required to pay annual management fees during each Fund's investment period based on the entire amount of such partner's commitments. There also is likely to be increasing competition among private equity firms and investors for investments in the sectors in which the Funds are targeting its investments. There are a number of partnerships and many experienced individuals in these industries that specialize in healthcare, life science and other science-based businesses. In addition, many established private equity firms and large private and public companies, which have much greater capital resources than the Funds, often invest in healthcare, life science and other science-based businesses. Therefore, there can be no assurance that any Fund will make a sufficient number of attractive investments in order to deploy the Fund's committed capital completely or profitably.

- Illiquidity; Lack of Current Distributions: An investment in any Linden Fund should be viewed as illiquid. It is uncertain as to when profits, if any, will be realized. Losses on unsuccessful investments may be realized before gains on successful investments are realized. The return of capital and the realization of gains, if any, generally will occur only upon the partial or complete disposition of an investment. While an investment may be sold at any time, it is not generally expected that this will occur for five years after the initial investment. Before such time, there may be no current return on the investment. Furthermore, the expenses of operating each Fund (including the annual management fee payable to its general partner) may exceed income, thereby requiring that the difference be paid from such Fund's capital.
- Limited Transferability of Fund Interests: There will be no public market for the Funds' interests, and none is expected to develop. There are substantial restrictions upon the transferability of any Fund interests under each Fund's partnership agreement and applicable securities laws. In general, withdrawals of Fund interests are not permitted. In addition, Fund interests are not redeemable.
- Restricted Nature of Investment Positions: Generally, there will be no readily available market for a substantial number of the investment recommendations, and hence, most of the client's investments will be difficult to value.
- Leveraged Investments: The Funds may make use of leverage by having a portfolio company incur debt to finance a portion of its investment in such portfolio company. Leverage generally magnifies both a Fund's opportunities for gain and its risk of loss from a particular investment. The cost and availability of leverage is highly dependent on the state of the broader credit markets, which state is difficult to accurately forecast. During times when credit markets are tight, it may be difficult to obtain or maintain the desired degree of leverage. Leverage often imposes restrictive financial and operating covenants on a company, in addition to the burden of debt service, and may impair its ability to finance future operations and capital needs. The leveraged capital structure of portfolio companies will increase the exposure of a Fund's investments to any deterioration in a company's condition or industry, competitive pressures, an adverse economic environment or rising interest rates and could accelerate and magnify declines in the value of a Fund's investments in the leveraged portfolio companies in a down market. In the event any portfolio company cannot generate adequate cash flow to meet debt service, such Fund may suffer a partial or total loss of capital invested in the portfolio company, which could adversely affect the returns of the Fund. Furthermore, should the credit markets be tight at the time a Fund determines that it is desirable to sell all or a part of a portfolio company, a Fund may not achieve an exit multiple or enterprise valuation consistent with its forecasts. Moreover, the companies in which the Funds will invest generally will not be rated by a credit rating agency.
- Uncertain Economic and Political Environment. The current global economic and political climate is one of uncertainty. The availability of credit for businesses, consumers and homeowners, including credit used to acquire businesses, is currently restricted. In addition, the fear of a prolonged global credit crisis has exacerbated volatility in the financial markets and can cause consumer, corporate and financial confidence to weaken, increasing the risk of

a “self-reinforcing” economic downturn. This may have an adverse effect on the economy generally and on the ability of the Funds and their portfolio companies to execute their respective strategies and to receive an attractive multiple of earnings on the disposition of their businesses. A climate of uncertainty may reduce the availability of potential investment opportunities and increase the difficulty of modeling market conditions, reducing the accuracy of the financial projections. Furthermore, such uncertainty, especially surrounding Medicare and Medicaid reimbursement, may have an adverse effect upon the portfolio companies in which the Funds make investments.

Item 9 – Disciplinary Information

Like other registered investment advisers, Linden is required to disclose all material facts regarding any legal or disciplinary events that would materially impact a limited partner’s evaluation of Linden or the integrity of Linden’s management. No events have occurred at Linden that are applicable to this Item.

Item 10 – Other Financial Industry Activities and Affiliations

Linden is not actively engaged in a business other than giving investment advice to its clients, the Funds (which are pooled investment vehicles), and managing the portfolio companies owned by its Funds. Neither Linden nor any of its management persons is registered or has an application pending to register as a broker-dealer, futures commission merchant, commodity pool operator, commodity-trading adviser, or associated person of the foregoing, and Linden does not anticipate such affiliations in the future.

In addition to his responsibilities at the Firm, one of Linden’s principals, Eric Larson, also engages in other strategic initiatives that are outside of Linden’s investment mandate.

Other than as discussed above, Linden has no other arrangements with a related person who is a broker-dealer, investment company, other investment adviser, financial planning firm, commodity pool operator, commodity trading adviser or futures commission merchant, banking or thrift institution, accounting firm, law firm, insurance company or agency, pension consultant, real estate broker or dealer, or an entity that creates or packages limited partnerships that are material to its advisory services, the Funds or its investors.

Linden has and will continue to develop professional relationships with professionals who provide services it does not provide, including: legal, accounting, banking, tax preparation, insurance brokerage, investment management services and other personal services. For example, Linden regularly uses McGladrey & Pullen, LLP as its Funds’ auditors and Kirkland & Ellis as its legal counsel. In the past, Linden has entered into written agreements with Park Hill Group LLC (“Park Hill”) to act on its behalf to solicit investors for its Funds. Linden is currently not, however, in fundraising mode and the Park Hill relationship is not active. None of these above relationships creates a conflict of interest with any Linden clients or investors.

From time to time, Linden receives training, information, promotional material, meals, gifts or prize drawings from vendors and others with whom it may do business or to whom it may make referrals. At no time will the Firm accept any benefits, gifts or other arrangements that are conditioned on directing individual client transactions to a specific security, product or provider.

Item 11 – Code of Ethics

Code of Ethics

Linden has adopted a Code of Ethics for all supervised persons of the Firm describing its high standard of business conduct and its responsibilities to its clients. Linden's Code of Ethics includes provisions relating to standards of business conduct, the confidentiality of client information, personal trading requirements, a prohibition on insider trading, a prohibition on rumor mongering, restrictions on the acceptance of significant gifts and the reporting of certain gifts and business entertainment items, social media policies, and political contribution policies, among other things. All Linden supervised persons must acknowledge and agree to be bound by the terms of the Code of Ethics annually, or at such time the Code of Ethics is amended.

Linden's clients or prospective clients may request a copy of the Firm's Code of Ethics by contacting its Chief Compliance Officer, Doug VanDegrift, at (312) 506-5600.

It is Linden's policy that the Firm will not affect any principal or agency cross securities transactions for client accounts. Linden will also not cross trades between client accounts. Principal transactions are generally defined as transactions where an adviser, acting as principal for its own account or the account of an affiliated broker-dealer, buys from or sells any security to any advisory client. A principal transaction may also be deemed to have occurred if a security is crossed between an affiliated fund and another client account. An agency cross transaction is defined as a transaction where a person acts as an investment adviser in relation to a transaction in which the investment adviser, or any person controlled by or under common control with the investment adviser, acts as broker for both the advisory client and for another person on the other side of the transaction.

Conflicts of Interest

The offering documents for each Fund details a complete description of what Linden believes to be the most significant conflicts of interest associated with an investment in the Fund. Some of these conflicts are summarized below; however, this summary does not attempt to describe all of the conflicts of interest associated with an investment in the Funds. Investors should carefully consider the conflicts of interest herein as well as those outlined in the Firm's offering documents prior to investing in a Fund.

Investors should note that there could be occasions when Linden and its affiliates may encounter potential conflicts of interest in connection with a Fund. If any matter arises that Linden determines in its good faith constitutes an actual conflict of interest, the Firm may take such actions as may be necessary or appropriate, within the context of such Fund's limited partnership agreement, to ameliorate the conflict (upon taking such actions Linden will be relieved of any responsibility for such conflict). These actions may include disposing of the asset giving rise to the conflict, bringing

the matter before Linden's advisory board or appointing an independent fiduciary to resolve the matter.

Linden will pursue all appropriate investment opportunities exclusively through its Fund vehicles. Linden, however, currently manages Funds I and II concurrently and each Fund may compete with the other for potential investment and/or exit opportunities. In its discretion, Linden will direct certain relevant investment opportunities to the particular Fund in which Linden believes will generate the most superior investment returns for its partners. Once each Fund's investment period concludes, Linden may and likely will focus its investment activities on other opportunities and areas unrelated to its current Funds' investments.

Certain Linden principals and employees are also investors in the Funds. However, because of the nature of its business, the participation of Linden employees in the Funds will not interfere with the making or implementing of decisions that are in the best interest of limited partners. Employee limited partners share in the same deals as other limited partners of the Funds, share costs, except for Management Fees, and receive distributions proportionally with other limited partners.

The significant investment of Linden principals in each of its Funds, as well as the principals' interest in the carried interest, operate to align, to some extent, Linden's interest with the interest of its Funds' limited partners. Although, Linden has economic interests in all of its Funds and investments, through its interest in each Fund, and receives management fees and carried interest fees with respect to each of its Funds. In addition, Linden employees may serve on the boards of Fund portfolio companies. Serving in such a capacity may give rise to conflicts to the extent that an employee's fiduciary duties to a portfolio company as a director may conflict with the interests of a Fund in general; however, as the Funds will generally be significant shareholders of such companies, it is expected that such interest will generally be aligned.

Each Fund's limited partners include persons or entities resident in various jurisdictions, including the United States and other countries, who may have conflicting investment, tax and other interests with respect to their investments in each Fund. The conflicting interests of individual limited partners may relate to or arise from, among other things, the nature of investments made by each Fund, the structuring of the acquisition of portfolio companies and the timing of disposition of investments. Such structuring of portfolio companies may result in different returns being realized by different limited partners. As a consequence, conflicts of interest may arise in connection with decisions made by Linden that may be more beneficial for one limited partner than another limited partner, especially with respect to limited partners' individual tax situations. Linden considers the investment and tax objectives of each Fund as a whole, and not the individual investment, tax or other objectives of any particular limited partner.

Linden may enter into individual agreements with a limited partner regarding a subscription in a Fund. These agreements are referred to as side letters, and may encompass a broad range of agreed-upon terms.

Item 12 – Brokerage Practices

The adviser will periodically engage broker-dealers to perform various services for its Funds, and/or its portfolio companies, such as assisting in the purchase or sale of a portfolio company. Broker-dealers are chosen based upon their knowledge and expertise in a given segment of the healthcare and life science industries as well as upon the cost of the services provided.

To the extent required by applicable law, it is Linden's policy to seek to obtain best execution of trades (if any) in public equity and debt securities and other Marketable Securities traded on behalf of the Funds by a selected broker-dealer. In seeking best execution, the determinative factor is not always the lowest possible per security price or commission but whether, in Linden's view, the transaction represents the best overall qualitative and quantitative execution for the Fund. Linden's process of determining best execution involves not only an assessment of brokerage commissions or bid/offer spreads, but also an evaluation of broker-dealer ancillary services. Linden will consider the full range of a broker-dealer's services in assessing best execution, including:

- A broker's execution capabilities with respect to the relevant type of order
- Commissions charged by a broker and whether the receipt of products or services is involved
- Reputation and responsiveness to requests
- Competitiveness of commission rates and spreads
- Value of privacy considerations, liquidity and price improvement
- Trade error rate and ability or willingness to correct errors
- Clearance and settlement capabilities
- Expertise with complex transactions

Although Linden will seek competitive commissions and spreads, it may not necessarily obtain the lowest possible rate for Fund transactions. The commissions, spreads or other financial advisory fees charged by an executing broker-dealer may be higher or lower than those charged by other broker-dealers.

The Firm does not receive any soft dollar benefits from a broker-dealer or other third party in connection with client securities transactions.

Item 13 – Review of Accounts

Doug VanDegrift, Controller and Chief Compliance Officer, reviews the accounts of each of its Funds on a quarterly basis. Mr. VanDegrift, in his role as Controller and Chief Compliance Officer, also reviews the Funds' accounts whenever a determination is made as to a distribution. Linden

furnishes to its limited partners unaudited financial statements for the first three quarters of each fiscal year within 45 days of each quarter's close and an annual audited financial statement within 90 days of the fiscal year end. Linden reviews the valuation of each client-held portfolio company quarterly and makes adjustments as necessary. In addition to providing client financial statements on a quarterly basis, Linden provides an individual statement of account for each limited partner quarterly. All reports are sent to investors in writing, and are delivered electronically.

Item 14 – Client Referrals and Other Compensation

Linden receives compensation in the form of fees paid by the limited partners, as disclosed in the limited partnership agreement. In addition, the Fund I and Fund II general partners may receive a closing fee upon the closing of a portfolio company transaction or a fee for providing management services to a portfolio company.

Linden may, from time to time, enter into solicitation agreements pursuant to which it compensates one or more third parties for client referrals that will result in the provision of investment advisory services by Linden. Any cash solicitation agreements will comply with Rule 206(4)-3 of the Advisers Act. Solicitors introducing investors to Linden may receive compensation from Linden, such as a retainer and/or a percentage of introduced capital. Such compensation is paid pursuant to a written agreement with the solicitor and typically may be terminated by either party from time to time. The cost of any such fees will be borne entirely by Linden and not by any affected investors. In connection with fundraising for Funds I and II, Linden hired Park Hill to solicit investors on its behalf. Linden is currently not, however, in fundraising mode and Park Hill is not actively soliciting investors on Linden's behalf.

Linden has engaged several individuals ("Operating Partners") to research, identify and provide recommendations regarding target markets, market segments and companies for potential acquisition or investment. Pursuant to written arrangements, Operating Partners are compensated through regular service payments and an additional fee paid upon the successful acquisition of a portfolio company sourced by such Operating Partner.

Item 15 – Custody

Linden generally has custody over the assets of each of the Linden Funds. Funds I and II receive annual audited financial statements from the Funds' auditors, McGladrey & Pullen, LLP. Linden forwards a copy of the audited financial statement to limited partners within 90 days of the fiscal year end.

By its ability to deduct performance fees from investor accounts, Linden is deemed to have custody over such funds. Linden, however, does not take physical possession of client money or securities; called capital is directly sent or wired into Linden's custodial accounts at BMO Harris Bank. BMO Harris Bank serves as a qualified custodian for all limited partner cash accounts and The Kingdom Trust Company ("Kingdom") serves as a qualified custodian for all limited partner securities accounts. Linden receives monthly statements from Harris Bank and quarterly statements from The

Kingdom Trust. On a quarterly basis, investors receive from Linden financial statements of the Fund they are invested in, an update on the Fund's portfolio company holdings, and a summary of each limited partner's capital account.

Item 16 – Investment Discretion

Linden and its general partners have discretionary authority based on management agreements with each of its Funds, and the limited partnership agreements that govern each Fund, to buy and sell securities or other investments on behalf of the Funds and to determine the amount of such investments to be bought and sold. The terms upon which Linden serves as an investment manager of a Fund are established at the time each Fund is established and are generally set out in the limited partnership agreement or other governing document entered into by Linden with respect to the relevant Fund and disclosed in the offering documents for such Fund, as applicable. These terms potentially restrict Linden's advice concerning investments in certain securities or types of securities, diversification, geographies, industries and leverage. Linden's authority to trade securities may also be limited by certain federal securities and tax laws that require diversification of investments and favor the holding of investments once made. No limited partners to date have limited Linden's discretion to provide investment advice, nor have any limited partners limited Linden's ability to invest in specific portfolio company sectors or otherwise.

To become a limited partner in a Linden Fund, an investor must execute a subscription agreement and a limited partnership agreement with such Fund. Linden is not required to contact a limited partner prior to transacting any business once a limited partner executes these documents.

Item 17 – Voting Client Securities

As of the date of this filing, Linden does not vote proxies on behalf of its Funds. In the event that this changes, the Firm will adopt a Proxy Voting Policy as required by Rule 206(4)-6 under the Advisers Act to ensure that it votes proxies in the best interests of its clients and will amend this Item 17 accordingly.

Item 18 – Financial Information

Registered investment advisers are required in this Item 18 to provide certain financial information or disclosures about Adviser's financial condition. Adviser has no financial commitment that impairs its ability to meet contractual and fiduciary commitments to clients, and has not been the subject of a bankruptcy proceeding.

BROCHURE SUPPLEMENT

This brochure supplement provides information about Linden Manager LLC (“Linden”) that supplements the Linden brochure. You should have received a copy of that brochure. Please contact Doug VanDegrift, Chief Compliance Officer, at (312) 506-5600 if you did not receive the Linden brochure or if you have any questions about the contents of this supplement.

Additional information about Linden is available on the SEC’s website at www.adviserinfo.sec.gov.

Anthony B. Davis

Year of Birth: 1970

Partner

Linden

111 S. Wacker Dr.

Suite 3350

Chicago, IL 60606

(312) 506-5600

Item 2 – Educational Background and Business Experience

Mr. Davis has been involved in principal investing and consulting since 1992. Prior to founding Linden, he was a Partner with One Equity Partners (formerly First Chicago Equity Capital, or “FCEC”) and Cambridge Capital Partners. Mr. Davis was previously a strategy and operations management consultant with Cresap, McCormick and Paget in Chicago and Hong Kong. Mr. Davis currently serves on the boards of directors of Behavioral Centers of America and Drayer Physical Therapy Institute, both portfolio companies held by Linden Funds.

Mr. Davis holds a Bachelor of Arts with honors in Economics from Northwestern University and an MBA with honors from the University of Chicago Graduate School of Business, where he was a Rosett Scholar and serves as a guest lecturer on private equity.

Item 3 – Disciplinary Information

Mr. Davis has never been the object of any legal or disciplinary event, proceeding or action.

Item 4 – Other Business Activities

As stated above, Mr. Davis serves on the boards of directors of Behavioral Centers of America and Drayer Physical Therapy Institute. Each of these aforementioned companies are Linden Fund portfolio companies and Mr. Davis’ appointment on such boards has been designated in the best interest of the Funds and their respective limited partners. Serving on portfolio company boards could lead to potential conflicts of interest. For example, a conflict of interests may arise between Mr. Davis’ fiduciary duties to the portfolio company on which he serves and his duty to Linden as decisions that are in the portfolio companies’ best interest may possibly not be in Linden’s best interests. As the Funds are generally significant shareholders of such companies, it is expected that such interest will generally be aligned; however, appropriate measures have been taken whereby Mr. Davis may recuse himself in such circumstances from the decision-making process.

Mr. Davis is a member of the Economic Club of Chicago, Chicago Council on Global Affairs and the Northwestern Memorial Hospital Foundation board.

Item 5 – Additional Compensation

Mr. Davis does not receive an economic benefit for providing advisory services, other than the regular salary and bonus paid by Linden and his direct investment interest in the investment Funds managed by Linden.

Item 6 – Supervision

Mr. Davis does not provide financial advice directly to clients. He is supervised by Linden's Chief Compliance Officer, Doug VanDegrift, (312) 506-5600.

Eric C. Larson

Year of Birth: 1954

Partner

Linden

111 S. Wacker Dr.

Suite 3350

Chicago, IL 60606

(312) 506-5600

Item 2 – Educational Background and Business Experience

Eric Larson has been involved in principal investing since 1985. Prior to founding Linden, Mr. Larson was Executive Vice President and Managing General Partner of FCEC, which he co-founded in 1991. He was previously a partner and investment principal at First Chicago Venture Capital, now Madison Dearborn Partners. Mr. Larson joined The First National Bank of Chicago in 1984 in its First Scholar management training program. Mr. Larson has been a board member of over a dozen public and private companies, including several roles as non-executive chairman. Mr. Larson currently serves on the boards of directors of Behavioral Centers of America and CORPAK MedSystems, both portfolio companies held by Linden Funds.

Mr. Larson holds an AB in Biology from Harvard College and an MBA from the University of Chicago Graduate School of Business.

Item 3 – Disciplinary Information

Mr. Larson has never been the object of any legal or disciplinary event, proceeding or action.

Item 4 – Other Business Activities

From time to time, Mr. Larson may spend time on other strategic initiatives that are outside of Linden's investment mandate ("Strategic Initiative"). As an unrelated line of work, Mr. Larson's other strategic initiatives do not create a potential conflict of interest with Linden's clients.

As stated above, Mr. Larson serves on the boards of directors of Behavioral Centers of America and CORPAK MedSystems. Each of these aforementioned companies are Linden portfolio companies and Mr. Larson's appointment on such boards has been designated in the best interest of the Funds and their respective limited partners. Serving on portfolio company boards could lead to potential conflicts of interest. For example, a conflict of interests may arise between Mr. Larson's fiduciary duties to the portfolio company on which he serves and his duty to Linden as decisions that are in the portfolio companies' best interest may possibly not be in Linden's best interests. As the Funds are generally significant shareholders of such companies, it is expected that such interests will generally be aligned; however, appropriate measures have been taken whereby Mr. Larson may recuse himself in such circumstances from the decision-making process.

He is a member of the boards of the Nutrition Roundtable at the Harvard School of Public Health, the National Center for Food Safety and Technology and the Chicago Botanic Garden. Mr. Larson also has affiliations with several science-related institutions.

Item 5 – Additional Compensation

In addition to his regular salary and bonus paid by Linden and his direct investment interest in the investment Funds managed by Linden, Mr. Larson receives a management fee and has the potential for capital appreciation through his direct investment and gain sharing arrangement with his Strategic Initiative. Other than those described in the previous sentence, Mr. Larson does not receive an economic benefit for providing advisory services.

Item 6 – Supervision

Mr. Larson does not provide financial advice directly to clients. He is supervised by Linden's Chief Compliance Officer, Doug VanDegrift, (312) 506-5600.

Brian C. Miller

Year of Birth: 1974

Partner

Linden

111 S. Wacker Dr.

Suite 3350

Chicago, IL 60606

(312) 506-5600

Item 2 – Educational Background and Business Experience

Brian Miller has been involved in principal investing and investment banking since 1996. Prior to founding Linden, he was an associate with the healthcare and life science team at FCEC. Mr. Miller began his career in the investment banking division of Salomon Brothers Inc. (currently Citigroup Global Markets Inc.). He currently serves on the boards of directors of Hycor Biomedical, StrataDX and CORPAK MedSystems, all portfolio companies of Linden clients.

Mr. Miller holds a Bachelor of Arts with honors in Economics from Princeton University and an MBA from Harvard Business School, with a concentration in healthcare.

Item 3 – Disciplinary Information

Mr. Miller has never been the object of any legal or disciplinary event, proceeding or action.

Item 4 – Other Business Activities

As stated above, Mr. Miller serves on the boards of directors of Hycor Biomedical, StrataDX and CORPAK MedSystems. Each of these aforementioned companies is a portfolio company of a Linden Fund and Mr. Miller's appointment on such boards has been designated in the best interest of the Funds and their respective limited partners. Serving on portfolio company boards could lead to potential conflicts of interest. For example, a conflict of interests may arise between Mr. Miller's fiduciary duties to the portfolio company on which he serves and his duty to Linden as decisions that are in the portfolio companies' best interest may possibly not be in Linden's best interests. As the Funds are generally significant shareholders of such companies, it is expected that such interest will generally be aligned; however, appropriate measures have been taken whereby Mr. Miller may recuse himself in such circumstances from the decision-making process.

Mr. Miller is the founder and President of the Healthcare Private Equity Association and is a member of the Economic Club of Chicago.

Item 5 – Additional Compensation

Mr. Miller does not receive an economic benefit for providing advisory services, other than the regular salary and bonus paid by Linden and his direct investment interest in the investment Funds managed by Linden.

Item 6 – Supervision

Mr. Miller does not provide financial advice directly to clients. He is supervised by Linden's Chief Compliance Officer, Doug VanDegrift, (312) 506-5600.

John E. Neal

Year of Birth: 1950

Special Partner

Linden

111 S. Wacker Dr.

Suite 3350

Chicago, IL 60606

(312) 506-5600

Item 2 – Educational Background and Business Experience

John (“Jack”) Neal has over 30 years of experience in executive positions in the financial services and banking industries. Mr. Neal previously served on the board of directors of Focused Health Solutions and Ranir, both prior portfolio companies of Linden. Prior to Linden, Mr. Neal began his career with Continental Bank, serving 18 years in real estate lending and becoming executive vice president and head of the real estate department, was Managing Director and Head of Corporate Banking at Bank One, served on the investment committee of One Equity Partners and was the President and Chief Operating Officer of Kemper Financial.

Mr. Neal holds an AB from Harvard College and an MBA from Harvard Business School.

Item 3 – Disciplinary Information

Mr. Neal has never been the object of any legal or disciplinary event, proceeding or action.

Item 4 – Other Business Activities

Mr. Neal serves on the financial services investments advisory board of CIVC Partners (“CIVC”) and on the board of directors of Calamos Mutual Funds (“Calamos”) and Equity Residential. Serving on the boards could lead to potential conflicts of interest. For example, through his role on the advisory board of CIVC, a private equity fund, Mr. Neal may be made aware of confidential information that could directly impact Linden and its current or future portfolio. This is considered remote as CIVC does not hold itself out as investors specializing in the healthcare or life science industries, and Calamos and Equity Residential do not make private equity investments. In the unusual circumstance that Mr. Neal is conflicted appropriate measures have been taken whereby he may recuse himself from the decision-making process.

Item 5 – Additional Compensation

In addition to his regular salary and bonus paid by Linden, Mr. Neal has a direct investment interest in the investments Funds managed by Linden. He also receives cash compensation for his role on the CIVC financial services investments advisory board and cash and stock compensation for his role on the Calamos and Equity Residential board of directors.

Item 6 – Supervision

Mr. Neal does not provide financial advice directly to clients. He is supervised by Linden’s Chief Compliance Officer, Doug VanDegrift, (312) 506-5600.

Douglass W. VanDegrift

Year of Birth: 1976

Chief Compliance Officer and Controller

Linden LLC

111 S. Wacker Dr.

Suite 3350

Chicago, IL 60606

(312) 506-5600

Item 2 – Educational Background and Business Experience

Doug VanDegrift joined Linden in 2010 with responsibility for financial, regulatory and administrative operations. He is a CPA with over 10 years of public accounting experience. From 2003 to 2010, Mr. VanDegrift worked as a Director at McGladrey & Pullen LLP primarily in their financial services practice group performing audits of private equity funds. Prior to McGladrey & Pullen LLP, he was with Doeren Mayhew, PC.

Mr. VanDegrift received his Bachelor of Arts in Accounting from Michigan State University in 1998.

Item 3 – Disciplinary Information

Mr. VanDegrift has never been the object of any legal or disciplinary event, proceeding or action.

Item 4 – Other Business Activities

Mr. VanDegrift is not actively engaged in any outside business activities or occupation for compensation that could potentially create a conflict of interest with clients.

Item 5 – Additional Compensation

Mr. VanDegrift does not receive an economic benefit for providing advisory services, other than the regular salary and bonus paid by Linden.

Item 6 – Supervision

Mr. VanDegrift does not provide financial advice directly to clients. He is supervised by Linden Partners Anthony Davis, Eric Larson, Brian Miller and Jack Neal, (312) 506-5600.